NEWS-INFO

Expanding Access to High-Quality Oral Solid Dosage Pharmaceuticals

At Innogenix, we are committed to delivering reliable, high-quality oral solid dosage pharmaceuticals that support healthcare providers, pharmacies, and patients across a broad range of therapeutic areas. Our growing portfolio includes tablets and capsules manufactured to meet stringent USP standards while offering flexible packaging configurations for institutional, retail, and unit-dose applications.

Comprehensive Oral Solid Dosage Portfolio

Our portfolio features a diverse selection of medications designed to address cardiovascular, neurological, psychiatric, gastrointestinal, and specialty care needs. Products are available in multiple strengths and pack sizes to support efficient dispensing and patient adherence.

Key Products Include:

Metronidazole Tablets, USP — available in 125 mg, 250 mg, and 500 mg strengths

Baclofen Tablets, USP — offered in 5 mg, 10 mg, and 20 mg strengths with bulk packaging options

Pilocarpine HCl Tablets, USP — available in 5 mg and 7.5 mg strengths

Labetalol HCl Tablets, USP — available in 100 mg, 200 mg, and 300 mg strengths

Metolazone Tablets, USP — available in 2.5 mg, 5 mg, and 10 mg strengths

Propranolol HCl Tablets, USP — ranging from 10 mg to 80 mg

Haloperidol Tablets, USP — available in multiple strengths from 0.5 mg to 20 mg

Captopril Tablets, USP — available from 12.5 mg through 100 mg

Ramelteon Tablets — 8 mg strength for sleep disorder management

Dofetilide Capsules — available in 0.125 mg, 0.25 mg, and 0.5 mg strengths

Flexible Packaging Solutions

To support varying distribution and dispensing needs, Innogenix offers both standard bottle packaging and blister unit-dose formats. Bulk pack sizes ranging from 100-count to 1000-count bottles help meet institutional and retail pharmacy requirements.

Our blister and unit-dose portfolio includes products such as:

Haloperidol Tablets

Baclofen Tablets

Captopril Tablets

Metronidazole Tablets

Metolazone Tablets

Blister packaging configurations are designed to improve medication organization, dosing accuracy, and patient compliance, making them ideal for hospitals, long-term care facilities, and outpatient settings.

Commitment to Quality and Reliability

Innogenix continues to focus on manufacturing excellence, regulatory compliance, and dependable supply chain support. By maintaining a broad and versatile product portfolio, we aim to provide healthcare partners with consistent access to essential medications in the formats they need most.

For more information about our product offerings, packaging configurations, or distribution opportunities, visit Innogenix or contact our team directly.

Innogenix Strengthens Strategic Collaboration and Industry Engagement

Innogenix continues to explore and strengthen collaborative opportunities within the pharmaceutical industry, including potential partnerships with development organizations, raw material suppliers, and commercial stakeholders.

The company remains actively engaged in discussions focused on in licensing opportunities, product development collaborations, and supply chain optimization initiatives. These engagements are intended to support expanded market access and enhance the availability of high quality generic pharmaceutical products.

Innogenix also continues to participate in industry forums and professional networks to stay aligned with evolving regulatory, scientific, and market trends.

Innogenix Advances Pipeline Development in Complex Generic Pharmaceuticals

Innogenix continues to progress its development efforts in complex and niche generic pharmaceutical products. The company’s focus remains on identifying formulations that present technical challenges in development and manufacturing, with the goal of expanding access to affordable and high quality medicines.

Current development activities include evaluation of multiple product opportunities across different therapeutic categories, with an emphasis on formulation feasibility, scalability, and regulatory pathway assessment. The pipeline strategy is aligned with long-term growth in specialty generics and limited competition markets.

Innogenix Enhances Focus on Quality and Manufacturing Excellence

Innogenix continues to strengthen its commitment to quality, compliance, and operational excellence across all areas of its pharmaceutical manufacturing and development activities. The company is actively enhancing internal systems, documentation practices, and process controls to ensure continued alignment with current Good Manufacturing Practices (cGMP) and evolving regulatory expectations.

As part of its ongoing improvement initiatives, Innogenix is also investing in training programs and cross-functional collaboration between manufacturing, quality assurance, and regulatory teams. These efforts are aimed at ensuring consistent product quality, operational efficiency, and long-term reliability in the supply of generic pharmaceuticals.